GCT is pleased to announce the successful completion of patient recruitment for the Phase III comparative double-blind clinical trial.

The aim of this study is to compare the efficacy, safety and immunogenicity of the sponsor’s drug versus a comparator therapy in patients with chronic idiopathic (immune) thrombotic thrombocytopenic purpura (ITP). Chronic ITP is a disorder characterized by an abnormally low level of platelets in the blood, leading to excessive bruising and bleeding.

We thank the Sponsor team for their trust and our colleagues for their proactive efforts in achieving this milestone. The completion of patient enrollment marks a significant step forward in Sponsor’s clinical research efforts. We look forward to continued collaboration until the final study report is produced, which will provide valuable insights into the treatment of this challenging condition.